Citadel Advisors
LMNL

Citadel Advisors’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Citadel Advisors’s Portfolio LMNL Stock Details LMNL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,240
Closed -$33K – 14538
2022
Q1 		$33K Sell
3,240
-670
-17% -$6.28K ﹤0.01% 13060
2021
Q4 		$43K Buy
3,910
+2,690
+220% +$40.3K ﹤0.01% 13328
2021
Q3 		$28K Sell
1,220
-1,170
-49% -$33.7K ﹤0.01% 13589
2021
Q2 		$93K Buy
+2,390
New +$104K ﹤0.01% 12974

Other funds holding LMNL

National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ECM
Estabrook Capital Management New York $685M AUM 26.64% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Citadel Advisors's LMNL Position: Q3 2022 in Review

Citadel Advisors sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q3 2022, closing a stake of 2,617 shares — an estimated $13K sold.

Citadel Advisors first reported a position in LMNL in Q2 2020 and held it in 5 quarters. The position peaked at $188K in Q2 2021. 15 funds tracked by Wall St. Rank hold LMNL as of Q3 2022.

  • Citadel Advisors reported no remaining Liminal BioSciences Inc. Common Shares position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 2,617 Liminal BioSciences Inc. Common Shares shares in Q3 2022, an estimated $13K.
  • Citadel Advisors first reported a position in Liminal BioSciences Inc. Common Shares in Q2 2020 and held it in 5 quarters.
  • Citadel Advisors's Liminal BioSciences Inc. Common Shares position peaked at $188K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.